Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

INFLIXIMAB-DYYB vs INFLUENZA VIRUS VACCINE QUADRIVALENT TYPE A+B: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

INFLIXIMAB-DYYB vs INFLUENZA VIRUS VACCINE QUADRIVALENT TYPE A+B: Safety Overview

Metric INFLIXIMAB-DYYB INFLUENZA VIRUS VACCINE QUADRIVALENT TYPE A+B
Total FAERS Reports 25,585 215
Deaths Reported 632 36
Death Rate 2.5% 16.7%
Hospitalizations 6,251 109
Average Patient Age 48.5 yrs 63.9 yrs
% Female Patients 54.0% 61.4%
Manufacturer CELLTRION USA Inc. N/A
Route SUBCUTANEOUS N/A
Marketing Status Prescription N/A